Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 32

Sort by

Sort Order Select

Journal Articles

The Impact of Sorafenib on Phospho-FLT3 Inhibition and FLT3 -ITD MRD after Chemotherapy: Correlative Studies from the Phase 2 Randomized Study of Sorafenib Versus Placebo in Combination with Intensive Chemotherapy in Previously Untreated Patients with FLT3 -ITD Acute Myeloid Leukemia (ALLG AMLM16)

Natasha S Anstee, PhD, Giovanna Pomilio, Mark Levis, MD PhD, Sarah MacRaild, Michael Murray, PhD DSc, Tristan Rawling, PhD, Glen A Kennedy, MBBS FRACP FRCPA, Andrew Grigg, MBBS, MD FRACP, FRCPA, Anthony Schwarer, MBBS, MD FRACP, FRCPA, Anoop Kumar Enjeti, MBBS,FRCPA, FRACP, PhD MD MRCP, James D'Rozario, MBBS, FRACP, FRCPA, Paula Marlton, MBBS FRACP FRCPA, Ian Bilmon, BMBS, FRACP, FRCPA, Adam Ivey, BSc, MSc, PhD, Doen Ming Ong, MBBS, Andrew W Roberts, MBBS, Andrew H Wei, MBBS, PhD

Blood (2020) 136 (Supplement 1): 16–18.

https://doi.org/10.1182/blood-2020-141711

Published: 2020

Journal Articles

Sabatolimab (MBG453) Dose Selection and Dose-Response Analysis in Myelodysplastic Syndrome (MDS)/Acute Myeloid Leukemia (AML): Population Pharmacokinetics (PK) Modeling and Evaluation of Clinical Efficacy/Safety By Dose

Blood (2020) 136 (Supplement 1): 40–42.

https://doi.org/10.1182/blood-2020-137307

Published: 2020

Journal Articles

Delays in Time to Deterioration of Health-Related Quality of Life Were Observed in Patients with Acute Myeloid Leukemia Receiving Venetoclax in Combination with Azacitidine or in Combination with Low-Dose Cytarabine

Blood (2020) 136 (Supplement 1): 33–35.

https://doi.org/10.1182/blood-2020-133912

Published: 2020

Journal Articles

Results of a Phase 2, Randomized, Double-Blind Study of Sorafenib Versus Placebo in Combination with Intensive Chemotherapy in Previously Untreated Patients with FLT3-ITD Acute Myeloid Leukemia (ALLG AMLM16)

Blood (2020) 136 (Supplement 1): 36–38.

https://doi.org/10.1182/blood-2020-137334

Published: 2020

Journal Articles

CC-486 Prolongs Survival for Patients with Acute Myeloid Leukemia (AML) in Remission after Intensive Chemotherapy (IC) Independent of the Presence of Measurable Residual Disease (MRD) at Study Entry: Results from the QUAZAR AML-001 Maintenance Trial

Gail J. Roboz, MD, Farhad Ravandi, MBBS, Andrew H Wei, MBBS, PhD, Hervé Dombret, MD, Hartmut Döhner, Felicitas Thol, Maria Teresa Voso, MD, Andre C. Schuh, Kimmo Porkka, Ignazia La Torre, Barry Skikne, MD, Keshava Kumar, PhD, Qian Dong, DrPH, C.L. Beach, PharmD, Alberto Risueño, Daniel Lopes de Menezes, PhD, Gert Ossenkoppele, MD PhD

Blood (2020) 136 (Supplement 1): 32–33.

https://doi.org/10.1182/blood-2020-140837

Published: 2020

Journal Articles

Results of Venetoclax and Azacitidine Combination in Chemotherapy Ineligible Untreated Patients with Acute Myeloid Leukemia with FLT3 Mutations

Marina Konopleva, MD PhD, Michael Thirman, MD, Keith W. Pratz, MD, Anthony G. Letai, MD PhD, Christian Recher, MD PhD, Vinod A. Pullarkat, MD, Hagop M. Kantarjian, MD, Monique Dail, PhD, Yinghui Duan, PhD, Brenda J. Chyla, Jalaja Potluri, MD, Catherine Miller, PharmD, Courtney D. Dinardo, MDMSc, Andrew H. Wei, MBBS, PhD

Blood (2020) 136 (Supplement 1): 8–10.

https://doi.org/10.1182/blood-2020-134100

Published: 2020

Journal Articles

Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients with Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS): Updated Results from a Phase 1b Study

Blood (2020) 136 (Supplement 1): 1–2.

https://doi.org/10.1182/blood-2020-136855

Published: 2020

Journal Articles

FT-2102, an IDH1m Inhibitor, in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Ayndrome (MDS): Results from a Phase 1 Study

Blood (2018) 132 (Supplement 1): 1452.

https://doi.org/10.1182/blood-2018-99-114126

Published: 2018

Journal Articles

PRMT5 Inhibition Selectively Targets Acute Myeloid Leukemia Stem Cells Though a p53-Dependent Mechanism

Emma Toulmin, PhD, Stefan Sonderegger, PhD MSc, Loretta Cerruti, BSc, Andrej Terzic, BSc, Feng Yan, BSc, Nicholas Wong, PhD, Ian Street, PhD, Paul Stupple, PhD, Stephen Jane, MD PhD, Andrew H Wei, MBBS, PhD, Rachel Altura, PhD, Benjamin Nicholson, PhD, David J. Curtis, MBBS,PhD

Blood (2018) 132 (Supplement 1): 4061.

https://doi.org/10.1182/blood-2018-99-117835

Published: 2018

Journal Articles

Development of a Data Portal for Aggregation and Analysis of Genomics Data in Familial Platelet Disorder with Predisposition to Myeloid Malignancy - the RUNX1.DB

Anna L. Brown, PhD BSc, Mark Armstrong, MSc, David Lawrence, Paul Wang, Peer Arts, PhD, Nicolas Duployez, PharmD, PhD, Jane Churpek, MD, Kiran Tawana, MD, Erin Degelman, MSc, BSc, Georges Natsoulis, PhD, Monica L. Guzman, PhD, Mrinal M. Patnaik, MD MBBS, Akiko Shimamura, MD PhD, Alan B. Cantor, MD PhD, Tim Ripperger, MD PhD, Brigitte Schlegelberger, MD PhD, Doris Steinemann, PhD, Courtney D. DiNardo, MD MSc, Cristina Mecucci, MD PhD, Elvira DRP Velloso, MD PhD, Fabio PS Santos, MD, Marcela CA Silva, Uma Borate, MD, Shannon K. McWeeney, PhD, Grzegorz Nalepa, MD PhD, Susanne Ragg, MD PhD, Erika Mijin Kwon, PhD, Anupriya Agarwal, PhD, Stephen Langabeer, PhD, Jeffery M. Klco, MD PhD, Jun J. Yang, PhD, Cecily Forsyth, FRACP, FRCPA, MBBS, Sally Mapp, MD PhD, Helen Mar Fan, MD, Lesley Rawlings, PhD, Rachel Susman, Sue Morgan, FRACP, FRCPA, MBBS, Andrew H Wei, MBBS,PhD, Inderjeet Dokal, MD, Tom Vulliamy, Devendra K Hiwase, MBBS, MD FRACP, FRCPA, PhD, Deepak Singhal, MBBS, MD FRACP, FRCPA, Susan Branford, PhD, Elli Papaemmanuil, PhD, Jean Soulier, MDPhD, Stefan Fröhling, MD, Alwin Kramer, MD, Guy Sauvageau, MD PhD, Neil Morgan, Carolyn Owen, Csaba Bödör, PhD, Jude Fitzgibbon, Hugh Y. Rienhoff, Jr., MD, Mineo Kurokawa, MD PhD, Lucy Godley, MD PhD, Claude Preudhomme, Paul P Liu, MD PhD, Nicola Poplawski, MD, Christopher N. Hahn, PhD, Hamish S. Scott, PhD

Blood (2018) 132 (Supplement 1): 5241.

https://doi.org/10.1182/blood-2018-99-118017

Published: 2018

Journal Articles

Ratify (Alliance 10603): Prognostic Impact of FLT3 tyrosine Kinase Domain (TKD) and NPM1 Mutation Status in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Treated with Midostaurin or Placebo Plus Standard Chemotherapy

Blood (2018) 132 (Supplement 1): 2668.

https://doi.org/10.1182/blood-2018-99-114318

Published: 2018

Journal Articles

Molecular Patterns of Response and Outcome in the Chemotherapy and Venetoclax in Elderly AML Trial (CAVEAT study)

Andrew H Wei, MBBS,PhD, Chong Chyn Chua, MBBS, BMedSc, Ing S Tiong, MBChB, Chun Yew Fong, MBBS,FRACP,FRCPA, Stephen B Ting, MB BS, FRACP, FRCPA, PhD, Sarah Macraild, Jessica M Salmon, PhD, Adam Ivey, BSc, MSc, PhD, John Nguyen, Flora Yuen, BBiomedSc, Richard Hall, Shaun Fleming, Stefan K. Bohlander, MD, John Reynolds, PhD, Andrew W. Roberts, MBBS, PhD

Blood (2018) 132 (Supplement 1): 333.

https://doi.org/10.1182/blood-2018-99-114243

Published: 2018

Journal Articles

Identification of Potent BH3-Mimetic Combinations Targeting Pro-Survival Pathways in Human B-Cell Acute Lymphoblastic Leukemia

Donia M Moujalled, PhD, Diane T Hanna, Giovanna Pomilio, Veronique Litalien, Shaun Fleming, Marie Chanrion, Ana-Leticia Maragno, Laurence Kraus-Berthier, Seong Lin Khaw, Guillaume Lessene, David Huang, Andrew W. Roberts, MBBS, PhD, Olivier Geneste, Paul G Ekert, Ashley P Ng, Andrew H Wei, MBBS,PhD

Blood (2018) 132 (Supplement 1): 567.

https://doi.org/10.1182/blood-2018-99-114051

Published: 2018

Journal Articles

FLT3 mutation Assay Laboratory Cross Validation: Results from the CALGB 10603/Ratify Trial in Patients with Newly Diagnosed FLT3 -Mutated Acute Myeloid Leukemia (AML)

Christian Thiede, MD, Thomas W Prior, MD, Serena Lavorgna, PhD, Jürgen Krauter, MD, Eva Barragán, Josep Nomdedeu, MD PhD, Joop H. Jansen, Andrew H Wei, MBBS, PhD, Weiqiang Zhao, MD PhD, Xiaohong Li, Celine Pallaud, PhD, Eva Tiecke, PhD, Richard A. Larson, MD, Clara D. Bloomfield, MD, Hartmut Döhner, MD, Gerhard Ehninger, MD, Richard M. Stone, MD, Konstanze Döhner, MD

Blood (2018) 132 (Supplement 1): 2800.

https://doi.org/10.1182/blood-2018-99-112127

Published: 2018

Journal Articles

Combined BCL-2 and HDAC Targeting Has Potent and TP53 Independent Activity in AML

Jessica M Salmon, PhD, Giovanna Pomilio, Donia M Moujalled, PhD, Sarah Macraild, Charis E Teh, PhD, Sewa Riajl, PhD, Adam Ivey, BSc, MSc, PhD, Tse-Chieh Teh, MD, Paul G Ekert, Laurence Kraus-Berthier, Ioana Kloos, Marie Schoumacher, Daniel Gray, Andrew H Wei, MBBS, PhD

Blood (2018) 132 (Supplement 1): 1426.

https://doi.org/10.1182/blood-2018-99-117403

Published: 2018

Journal Articles

KB004, a Novel Non-Fucosylated Humaneered® Antibody, Targeting EphA3, Is Active and Well Tolerated in a Phase I/II Study of Advanced Hematologic Malignancies

Ronan T Swords, MD PhD FRCPI, FRCPath, Andrew H Wei, MBBS, PhD, Simon Durrant, MBBS, MRCS, LRCP, FRCP, FRCPat, Anjali S. Advani, MD, Mark S Hertzberg, MBBS PhDFRACP FRCPA, Ian D Lewis, MBBS, PhD, Peter L. Greenberg, MD PhD, Jorge E. Cortes, MD, Geoff T Yarranton, PhD, Jackie M. Walling, MBChB, PhD, Jeffrey E. Lancet, MD

Blood (2014) 124 (21): 3756.

https://doi.org/10.1182/blood.V124.21.3756.3756

Published: 2014

Journal Articles

Eradication of Acute Myeloid Leukemia Is Enhanced By Combined Bcl-2 and Mcl-1 Targeting

Tse-Chieh Teh, MBBS, FRACP, FRCPA, Nhu-Y Nguyen, PhD, Stefan Glaser, PhD, Donia Moujalled, PhD, Giovanna Pomilio, David CS Huang, Mark Guthridge, Andrew H Wei, MBBS, PhD

Blood (2014) 124 (21): 988.

https://doi.org/10.1182/blood.V124.21.988.988

Published: 2014

Journal Articles

The Significance of GADD45A Promoter DNA Hypermethylation in AML: Association with IDH1/2 and TET2 Mutation

Michelle Perugini, PhD, Saumya E Samaraweera, PhD, Anna L Brown, PhD, Nik Cummings, BSc, Silke Danner, Ing Soo Tiong, MBChB, Francine E Garrett-Bakelman, MD PhD, Martin P. Carroll, MD, Michael W. Becker, MD, Stephen S. Chung, MD, Christopher Y. Park, MD PhD, Christopher E Mason, PhD, Monica L. Guzman, PhD, Ross L. Levine, MD, Ari M Melnick, MD, Luen Bik To, MBBS, PhD, Andrew H Wei, MBBS, PhD, Ian D Lewis, MBBS, PhD, Richard J D'Andrea, PhD

Blood (2014) 124 (21): 69.

https://doi.org/10.1182/blood.V124.21.69.69

Published: 2014

Journal Articles

Outpatient Non-Myeloablative Allogeneic Stem Cell Transplantation For Myeloma Is Feasible, Efficacious and Associated With Low Transplant-Related Morbidity and Mortality

Philip Campbell, MBBS, FRACP, FRCPA, Patricia A. Walker, MBBS, FRACP, FRCPA, Sharon Avery, MBBS, Sushrut S. Patil, FRACP, FRCPA, David J. Curtis, M.D., Ph.D., Anthony P. Schwarer, MD, Andrew H Wei, MBBS, PhD, Anna Kalff, MBBS, FRACP, FRCPA, Jenny Muirhead, Andrew Spencer, MD

Blood (2013) 122 (21): 2128.

https://doi.org/10.1182/blood.V122.21.2128.2128

Published: 2013

Journal Articles

Puma Is The Critical BH3-Only Protein Mediating Apoptosis In The Nup98-HoxD13 (NHD13) Mouse Model Of Human MDS

Andrew Guirguis, MBBS, FRACP, FRCPA, David J. Curtis, M.D., Ph.D., Christopher Slape, PhD, Jesslyn Saw, Andrew H Wei, MBBS, PhD, Laura M Failla, Philippe Bouillet, PhD, Andreas Strasser, PhD

Blood (2013) 122 (21): 1563.

https://doi.org/10.1182/blood.V122.21.1563.1563

Published: 2013

NARROW

The Impact of Sorafenib on Phospho-FLT3 Inhibition and FLT3 -ITD MRD after Chemotherapy: Correlative Studies from the Phase 2 Randomized Study of Sorafenib Versus Placebo in Combination with Intensive Chemotherapy in Previously Untreated Patients with FLT3 -ITD Acute Myeloid Leukemia (ALLG AMLM16)

Sabatolimab (MBG453) Dose Selection and Dose-Response Analysis in Myelodysplastic Syndrome (MDS)/Acute Myeloid Leukemia (AML): Population Pharmacokinetics (PK) Modeling and Evaluation of Clinical Efficacy/Safety By Dose

Delays in Time to Deterioration of Health-Related Quality of Life Were Observed in Patients with Acute Myeloid Leukemia Receiving Venetoclax in Combination with Azacitidine or in Combination with Low-Dose Cytarabine

Results of a Phase 2, Randomized, Double-Blind Study of Sorafenib Versus Placebo in Combination with Intensive Chemotherapy in Previously Untreated Patients with FLT3-ITD Acute Myeloid Leukemia (ALLG AMLM16)

CC-486 Prolongs Survival for Patients with Acute Myeloid Leukemia (AML) in Remission after Intensive Chemotherapy (IC) Independent of the Presence of Measurable Residual Disease (MRD) at Study Entry: Results from the QUAZAR AML-001 Maintenance Trial

Results of Venetoclax and Azacitidine Combination in Chemotherapy Ineligible Untreated Patients with Acute Myeloid Leukemia with FLT3 Mutations

Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients with Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS): Updated Results from a Phase 1b Study

FT-2102, an IDH1m Inhibitor, in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Ayndrome (MDS): Results from a Phase 1 Study

PRMT5 Inhibition Selectively Targets Acute Myeloid Leukemia Stem Cells Though a p53-Dependent Mechanism

Development of a Data Portal for Aggregation and Analysis of Genomics Data in Familial Platelet Disorder with Predisposition to Myeloid Malignancy - the RUNX1.DB

Ratify (Alliance 10603): Prognostic Impact of FLT3 tyrosine Kinase Domain (TKD) and NPM1 Mutation Status in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Treated with Midostaurin or Placebo Plus Standard Chemotherapy

Molecular Patterns of Response and Outcome in the Chemotherapy and Venetoclax in Elderly AML Trial (CAVEAT study)

Identification of Potent BH3-Mimetic Combinations Targeting Pro-Survival Pathways in Human B-Cell Acute Lymphoblastic Leukemia

FLT3 mutation Assay Laboratory Cross Validation: Results from the CALGB 10603/Ratify Trial in Patients with Newly Diagnosed FLT3 -Mutated Acute Myeloid Leukemia (AML)

Combined BCL-2 and HDAC Targeting Has Potent and TP53 Independent Activity in AML

KB004, a Novel Non-Fucosylated Humaneered® Antibody, Targeting EphA3, Is Active and Well Tolerated in a Phase I/II Study of Advanced Hematologic Malignancies

Eradication of Acute Myeloid Leukemia Is Enhanced By Combined Bcl-2 and Mcl-1 Targeting

The Significance of GADD45A Promoter DNA Hypermethylation in AML: Association with IDH1/2 and TET2 Mutation

Outpatient Non-Myeloablative Allogeneic Stem Cell Transplantation For Myeloma Is Feasible, Efficacious and Associated With Low Transplant-Related Morbidity and Mortality

Puma Is The Critical BH3-Only Protein Mediating Apoptosis In The Nup98-HoxD13 (NHD13) Mouse Model Of Human MDS

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only